Mehmet Ay

MedicineBiochemistry, Genetics and Molecular BiologyChemistryPharmacology, Toxicology and Pharmaceutics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Novel Inhibitors of Eukaryotic Elongation Factor 2 Kinase: In Silico, Synthesis, and in Vitro Studies”.

Novel Inhibitors of Eukaryotic Elongation Factor 2 Kinase: In Silico, Synthesis, and in Vitro Studies

ChemRxiv(2020)10.26434/chemrxiv.13299149.v1

N/A

0DataRank · unranked

1 citations

Serdar Durdağı, Nermin Kahraman, Tuğçe Nur Uslu, Hakan Kandemir, Esen Bellur Atıcı +3 more

Novel Inhibitors of Eukaryotic Elongation Factor 2 Kinase: In Silico, Synthesis, and in Vitro Studies

ChemRxiv(2020)10.26434/chemrxiv.13299149

N/A

0DataRank · unranked

1 citations

Serdar Durdağı, Nermin Kahraman, Tuğçe Nur Uslu, Hakan Kandemir, Esen Bellur Atıcı +3 more

Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth In Vivo

ACS Pharmacology & Translational Science(2021)10.1021/acsptsci.1c00030

N/A

0DataRank · unranked

17 citations

Nermin Kahraman, Esen Bellur Atıcı, Ali Çağır, Hakan Kandemir, Gizem Tatar +7 more